Publications by authors named "Erica Palesandro"

Claim this Profile
M
Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist.
Angelo Del Gaudio, Loris Riccardo Lopetuso, Valeria Pavese, Erica Palesandro, Ilaria Campisi

Therap Adv Gastroenterol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is [Lu]Lu-PSMA-617 Redefining Value in mCRPC Care? A Meta-Analysis of Clinical and Economic Endpoints.
Francesco Fiorica, Maria Viviana Candela, Teodoro Sava, Matteo Salgarello, Jacopo Giuliani, Erica Palesandro

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: Practical expert-based management recommendations.
Carla Colombo, Simone De Leo, Ilaria Campisi, Erica Palesandro, Fabio Turco

Crit Rev Oncol Hematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer: Biological Rationale and Systematic Review of Published Data.
Francesco Fiorica, Teodoro Sava, Jacopo Giuliani, Umberto Tebano, Giuseppe Napoli, Erica Palesandro

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives.
Fabio Turco, Consuelo Buttigliero, Marco Donatello Delcuratolo, Silke Gillessen, Ursula Maria Vogl, Erica Palesandro

Clin Genitourin Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials.
Marcello Tucci, Marta Mandarà, Jacopo Giuliani, Emilia Durante, Consuelo Buttigliero, Erica Palesandro

Cancer Treat Rev· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
Orazio Caffo, Cinzia Ortega, Franco Nolè, Donatello Gasparro, Claudia Mucciarini, Erica Palesandro

Eur J Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave.
Valentina Bertaglia, Maria Lucia Reale, Paolo Bironzo, Erica Palesandro, Annapaola Mariniello

Crit Rev Oncol Hematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Unit.
Maria Lucia Reale, Paolo Bironzo, Valentina Bertaglia, Erica Palesandro, Gianmarco Leone

Front Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
Gaetano Facchini, Sabrina Rossetti, Massimiliano Berretta, Carla Cavaliere, Sarah Scagliarini, Erica Palesandro

J Transl Med· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.
Andrea Sbrana, Elisa Biasco, Federico Paolieri, Erica Palesandro, Claudia Caserta

Anticancer Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.
Lorenzo D'Ambrosio, Erica Palesandro, Paola Boccone, Francesco Tolomeo, Sara Miano

Eur J Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-fetoprotein elevation in NUT midline carcinoma: a case report.
Lorenzo D'Ambrosio, Erica Palesandro, Marina Moretti, Giuseppe Pelosi, Alessandra Fabbri

BMC Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Ymera Pignochino, Federica Capozzi, Lorenzo D'Ambrosio, Carmine Dell'Aglio, Marco Basiricò, Erica Palesandro

Mol Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
Danilo Galizia, Erica Palesandro, Anna Maria Nuzzo, Ymera Pignochino, Sandra Aliberti

Oncol Res· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?
Fabrizio Carnevale-Schianca, Susanna Gallo, Delia Rota-Scalabrini, Dario Sangiolo, Marco Fizzotti, Erica Palesandro

J Clin Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis